Transplacental antibodies against Plasmodium falciparum Schizont Egress Antigen-1 may protect infants from severe malarial infection during the first year of life. This new knowledge about these antibodies potentially can inform vaccine development.
A new analysis of a national survey underscores the importance of continued efforts to strengthen practitioner adoption of evidence-based approaches to recommending the HPV vaccine.
Researchers are moving ahead with studies of a potential immunotherapeutic, nonsurgical approach to treating cervical intraepithelial neoplasia caused by human papillomavirus infection (HPV).
Multi-Modal Interventions for Controlling CRE: Which Is Best? Antimicrobial Resistance Genes — in the Arctic; Updated PEP Guidelines for Hepatitis A Vaccine
In a multi-year analysis of cervical precancers, data indicate that the incidence of cancers caused by human papillomavirus (HPV) types 16 and 18, which have been targeted by vaccination, has declined.
According to a new study, only about 16% of U.S. adolescents have received the complete vaccination against human papillomavirus (HPV) by the time they turn 13 years of age, despite national recommendations for vaccination at ages 11-12.
